

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 11/09/2006

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/807,942 03/24/2004		Kristof Chwalisz	ABB01259P00381US (7348.US	5147	
7590 11/09/2006			EXAMINER		
TAP Pharmaceutical Products, Inc. Attention: Mark J. Buonaiuto			HANDY, NIKKI R		
675 North Field Drive Lake Forest, IL 60045			ART UNIT	PAPER NUMBER	
			1616	•	

Please find below and/or attached an Office communication concerning this application or proceeding.

			n No.	Applicant(s)				
Office Action Summary		10/807,94	2	CHWALISZ, KRISTOF .				
		Examiner	•	Art Unit				
		Nikki Hand	<u> </u>	1616				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exter after - If NO - Failu Any r	CRTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE in any be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF TH 36(a). In no ever will apply and will cause the appli	IS COMMUNICATION nt, however, may a reply be tire expire SIX (6) MONTHS from cation to become ABANDONE	N. mely filed n the mailing date of this o ED (35 U.S.C. § 133).				
Status								
1)□	Responsive to communication(s) filed on							
	This action is FINAL . 2b) This action is non-final.							
·—								
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)⊠	☑ Claim(s) <u>1-15</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
	Claim(s) is/are allowed.							
6)	Claim(s) is/are rejected.							
7)								
8)⊠	Claim(s) <u>1-15</u> are subject to restriction and/or e	election requ	uirement.					
Applicati	on Papers							
9)[The specification is objected to by the Examiner	r.						
10) 🔲	The drawing(s) filed on is/are: a)☐ acce	epted or b)[objected to by the	Examiner.				
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	nder 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) 🗋 Notice 3) 🔲 Inforn	(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal P 6) Other:	ate	·			

Application/Control Number: 10/807,942

Art Unit: 1616

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-10, are drawn to a method for regulating a menstrual cycle comprising administering a selective progesterone receptor modulator during a first dosing period and at least one progestogen during a second dosing period, classified in class 514, subclass 177.
- II. Claims 11-13, are drawn to a method of treating a gynaecological disorder comprising administering to a patient a SPRM for a first dosing period, wherein the improvement comprises administering at least one progestogen during a second dosing period, classified in class 514, subclass 177.
- III. Claims 14 and 15, are drawn to a kit comprising a SPRM and at least one progestogen, classified in class 514, subclass 177.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the product as claimed can be used in a materially different process of using that product. For

Art Unit: 1616

example, the kit in the instant claims comprising a SPRM and at least one progestogen can also comprise a SPRM and an estrogen.

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different designs, modes of operation, and effects (MPEP § 802.01 and § 806.06). In the instant case, the different inventions are unrelated because one method is for regulating a menstrual cycle and the other method is for treating a gynaecological disorder. The methods have different effects thus the inventions are unrelated.

Notice of Possible Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder.

All claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not

Application/Control Number: 10/807,942

Art Unit: 1616

§ 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder**. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

A telephone call was made to Paul Yasger on October 17, 2006 to request an oral election to the above restriction requirement, but did not result in an election being made. Mr. Yasger is no longer the contact person for this case but stated that he would transfer the case to the appropriate person. The appropriate person has not made an oral election therefore this written action.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nikki Handy whose telephone number is (571) 272-9923. The examiner can normally be reached on Monday-Friday 8:30 am-5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/807,942 Page 5

Art Unit: 1616

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nikki Handy Patent Examiner Art Unit 1616

> Johann Richter, Ph. D., Esq. Supervisory Patent Examiner Technology Center 1600